24,532 Shares in Edwards Lifesciences Corporation $EW Purchased by Kingsview Wealth Management LLC

Key Points

• Kingsview Wealth Management purchased 24,532 Edwards Lifesciences shares worth approximately $2.2 million in the second quarter. Institutional investors collectively own 79.46% of the company.
• Edwards reported quarterly earnings of $0.78 per share, exceeding estimates by $0.04, while revenue rose 13.6% year over year to $1.74 billion. The company issued third-quarter 2026 EPS guidance of $0.71–$0.77.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $100.27, compared with the stock’s reported price of $90.19. Meanwhile, insiders sold 4,501 shares worth about $408,000 over the past 90 days.

Kingsview Wealth Management LLC purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 24,532 shares of the medical research company's stock, valued at approximately $2,219,000.

A number of other hedge funds also recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth approximately $5,318,092,000. State Street Corp lifted its position in Edwards Lifesciences by 1.5% in the fourth quarter. State Street Corp now owns 25,991,524 shares of the medical research company's stock worth $2,215,777,000 after purchasing an additional 371,892 shares during the period. Wellington Management Group LLP lifted its position in Edwards Lifesciences by 4.8% in the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company's stock worth $1,857,934,000 after purchasing an additional 989,533 shares during the period. Bank of New York Mellon Corp acquired a new stake in Edwards Lifesciences during the second quarter worth $1,274,082,000. Finally, Norges Bank acquired a new stake in Edwards Lifesciences during the fourth quarter worth $803,686,000. Institutional investors own 79.46% of the company's stock.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the business's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the transaction, the vice president owned 40,034 shares of the company's stock, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Bruls sold 2,644 shares of the stock in a transaction on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the sale, the vice president owned 17,984 shares in the company, valued at $1,618,200.32. The trade was a 12.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 4,501 shares of company stock worth $408,213. 0.31% of the stock is owned by corporate insiders.

Edwards Lifesciences Trading Up 0.3%

Shares of EW stock opened at $90.19 on Friday. The company has a market capitalization of $51.93 billion, a P/E ratio of 51.83, a P/E/G ratio of 2.37 and a beta of 0.85. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The firm has a 50-day moving average price of $89.54 and a 200 day moving average price of $85.03.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion for the quarter, compared to analysts' expectations of $1.70 billion. During the same period in the prior year, the firm earned $0.67 earnings per share. The company's quarterly revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Research analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the subject of a number of recent research reports. Mizuho increased their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an "outperform" rating in a research note on Wednesday, July 15th. Wall Street Zen lowered shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Saturday, July 4th. Piper Sandler reissued an "overweight" rating and issued a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Truist Financial raised their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "hold" rating in a research note on Thursday, July 16th. Finally, UBS Group started coverage on shares of Edwards Lifesciences in a research note on Tuesday, July 28th. They set a "buy" rating and a $110.00 price target for the company. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source